Conformal Medical Announces Leadership Expansion

NASHUA, N.H. – August 7, 2023 – Conformal Medical, Inc., a medical device company developing next-generation left atrial appendage occlusion (LAAO) technology, today announced the appointment of Melissa Farina as Chief Financial Officer. With over two decades in the medical device industry, Farina has senior finance leadership experience with both public and private companies. She joins Conformal following its recent Series D financing, which raised a total of $35 million to support ongoing enrollment of the company’s CONFORM Pivotal Trial, drive iterative development projects and broaden clinical experience in expanded geographies.

“I am excited to join Conformal Medical at this important time as the company advances its clinical program and further validates its technology,” states Farina. “The CLAAS® implant, with its conformable foam-based design, has the potential to simplify LAAO procedures, improve the patient experience, and expand access for patients. I look forward to being part of this talented team as we bring this much-needed solution to market.”

Farina has a proven track record of strong financial strategy execution. She recently served as CFO of Neuspera Medical, a start-up medical device company developing implantable technologies for patients battling chronic illness and was a core team member as the company initiated the second phase of its U.S. IDE clinical trial. Prior to Neuspera Medical, Farina served as CFO of the Medical Division of Halma PLC, where she led strategy, capital and resource allocation, and merger and acquisition activity, delivering on growth and profitability goals for the division. Earlier in her career, Farina held executive leadership positions at LivaNova and Becton Dickinson.

“We are delighted to welcome Melissa to the Conformal Medical team. She is an accomplished finance executive and proven leader,” commented James Reinstein, President and CEO of Conformal Medical. “Melissa’s expertise will add tremendous value as we accelerate clinical efforts and drive strategic initiatives towards commercialization.”


About Conformal Medical
Founded in 2016, Conformal Medical, Inc. is a medical device company developing solutions to prevent stroke in patients with non-valvular Afib. The company’s proprietary technology is intended to make left atrial appendage occlusion (LAAO) a same day, single operator procedure. For more information, visit https://conformalmedical.com/.

About Left Atrial Appendage Closure
More than six million people in the United States suffer from AFib, placing them at an increased risk of stroke.¹ Current standard of care for stroke prevention is chronic oral anticoagulants, which are not well accepted by patients due to concern about associated risk of bleeding. LAAO is emerging as an important alternative to blood thinners for preventing strokes in patients with non-valvular AFib. First-generation LAAO devices are an estimated $700M global market in 2021 and are expected to grow to over $3B in the next five years.^2,3

1. Kornej J, Börschel CS, Benjamin EJ, Schnabel RB. Epidemiology of Atrial Fibrillation in the 21st Century: Novel Methods and New Insights. Circ Res. 2020 Jun 19;127(1):4-20.
2. Boston Scientific Investor Presentation, September 2021.
3. Key Takeaways from the SVB Leerink Global Healthcare Conference, February 2022.